Press release
Enterobacteriaceae Infection Drug: A Guide to Understanding the Process
Enterobacteriaceae Infection Drug Market
Enterobacteriaceae are a large family of different types of germs (bacteria) that commonly cause infections in healthcare settings. Examples of germs in the Enterobacteriaceae family include Escherichia coli (E. coli) and Klebsiella pneumoniae.
MARKET DYNAMICS
Rising prevalence of Enterobacteriaceae infectious diseases, For instance, in 2021, CRE caused an estimated 13,100 infections in hospitalized patients, and 1,100 estimated deaths in the United States increasing modes of spread of the infectious disease and a lack of cleanliness are the driving factors. However, the major factor which will restrain the market growth rapid resistance to drugs currently available for enterobacter infections. Furthermore, launch of new antibiotics with activity against carbapenem-resistant Enterobacteriaceae (CRE) will offer lucrative opportunities in the market.
Get More Details with Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00008464?utm_source=OpenPR&utm_medium=10852
Enterobacteriaceae Infection Drug Market: Competitive Landscape and Key Developments:
1. Genentech, Inc.
2. Allergan
3. Novartis AG
4. Pfizer Inc.
5. Nymox Pharmaceutical Corporation
6. Sequoia Sciences, Inc.
7. Phico Therapeutics Ltd.
8. Melinta Therapeutics, Inc.
9. Spero Therapeutics
10. Cipla USA, Inc.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Ankit Mathur
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Enterobacteriaceae Infection Drug: A Guide to Understanding the Process here
News-ID: 3870165 • Views: …
More Releases from The Insight Partners
Green Building Materials Market Forecast 2031: Valued at US$ 791.93 Billion, Gro …
The Green Building Materials Market size is expected to reach US$ 791.93 billion by 2031. The market is anticipated to register a CAGR of 10.4% during 2025-2031.
Global Green Building Materials Market 2031 Report give our customers an exhaustive and top to bottom examination of Green Building Materials Market alongside its key factors, for example, market diagram and rundown, pieces of the pie, restrictions, drivers, local examination, players, serious elements, division,…
Text Analytics Market Growth Forecast: Valued at US$ 29.53 Billion by 2031
The Text Analytics Market is evolving rapidly, fueled by breakthroughs in artificial intelligence, natural language processing, and the exploding volume of unstructured data from social media, customer feedback, and enterprise communications. Businesses worldwide are turning to text analytics solutions to unlock hidden insights, enhance customer experiences, and drive data-informed strategies. As organizations navigate complex data landscapes, text analytics stands out as a critical tool for competitive advantage.
Download PDF: -https://www.theinsightpartners.com/sample/TIPTE100000198?utm_source=Openpr&utm_medium=10413
In today's…
Genome Editing Market: Trends, Opportunities, and Future Outlook
The genome editing market has emerged as one of the most dynamic and transformative sectors in biotechnology, driven by advancements in genetic engineering technologies and increasing applications across various fields. As of 2024, the market is witnessing significant growth, fueled by the rising demand for personalized medicine, agricultural innovations, and therapeutic solutions. This article explores the current trends, opportunities, and future outlook of the genome editing market.
Get the sample request…
Transdermal Drug Delivery System Market to Reach US$ 51,949.74 Million by 2030
The Transdermal Drug Delivery System Market is entering a new era of growth, driven by rising demand for non-invasive drug administration, patient-friendly therapies, and technological innovation. According to industry analysis, the market size is expected to grow from US$ 37,230.28 million in 2022 to US$ 51,949.74 million by 2030, recording a CAGR of 4.3% during 2022-2030. This trajectory highlights the increasing adoption of transdermal patches, gels, sprays, and other advanced…
More Releases for Enterobacteriaceae
Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Market is expected to re …
Carbapenem-resistant Enterobacteriaceae (CRE) represent one of the most dangerous groups of multidrug-resistant (MDR) bacteria, including Klebsiella pneumoniae and Escherichia coli. These pathogens are resistant to nearly all available antibiotics, including carbapenems, which are considered last-resort treatments.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71765
CRE infections are associated with high mortality rates (up to 50%), prolonged hospital stays, and major economic burden. They occur most often in hospitalized, immunocompromised, and…
Global Carbapenem-Resistant Enterobacteriaceae (CRE) Testing Market to Reach USD …
The global Carbapenem-resistant Enterobacteriaceae (CRE) testing market is experiencing significant growth, driven by the escalating prevalence of CRE infections and the imperative need for rapid, The global carbapenem-resistant enterobacteriaceae testing market is estimated at a value of US$ 4.25 billion in 2024 and is forecasted to reach a size of US$ 8.89 billion by 2034-end. Worldwide demand is projected to advance at a 7.7% CAGR from 2024 to 2034.
Market Development
The…
Enterobacteriaceae Infection Drug Market Trends, Research, Analysis & Forecast 2 …
The latest Enterobacteriaceae Infection Drug Market study offers an all-inclusive analysis of the major strategies, corporate models, and market shares of the most noticeable players in this market. The study offers a thoroughanalysis of the key persuading factors, market figures in terms of revenues, segmental data, regional data, and country-wise data. This study can be described as most wide-ranging documentation that comprises all the aspects of the evolving Enterobacteriaceae Infection…
Enterobacteriaceae Infection Drug Market Size, Share, Development by 2024
LP INFORMATION offers a latest published report on Enterobacteriaceae Infection Drug Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Enterobacteriaceae Infection Drug market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.…
Carbapenem-resistant Enterobacteriaceae Testing Market to Partake Significant De …
Enterobacteriaceae are a family of germs that most commonly live in a person’s bowel without causing any disease. Carbapenems are strong antibiotics that are commonly used to treat serious infections. A few enterobacteriaceaea have gained resistance to these antibiotics. These are called Carbapenem-resistant Enterobacteriaceae. Carbapenem-resistant Enterobacteriaceae testing is considered to be a gram-negative pathogen testing. Common gram-negative pathogens include Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, Enterobacter aerogenes and Acinetobacterbaumannii. These…
Carbapenem-resistant Enterobacteriaceae Testing Market Analysis, Segments, Growt …
Enterobacteriaceae are a family of germs that most commonly live in a person’s bowel without causing any disease. Carbapenems are strong antibiotics that are commonly used to treat serious infections. A few enterobacteriaceaea have gained resistance to these antibiotics. These are called Carbapenem-resistant Enterobacteriaceae. Carbapenem-resistant Enterobacteriaceae testing is considered to be a gram-negative pathogen testing. Common gram-negative pathogens include Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, Enterobacter aerogenes and Acinetobacterbaumannii.
These gram-negative…
